AIM ImmunoTech Inc. (AIM) News

AIM ImmunoTech Inc. (AIM): $0.83

-0.02 (-2.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AIM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 458

in industry

Filter AIM News Items

AIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AIM News From Around the Web

Below are the latest news stories about AIM ImmunoTech Inc that investors may wish to consider to help them evaluate AIM as an investment opportunity.

AIM ImmunoTech (AIM) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 26, 2022

AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID OCALA, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immu

Yahoo | January 26, 2022

AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical study Phase 2 study will be conducted to evaluate immunologic and clinical efficacy of tumor loaded αDC1 vaccine in conjunction with the cisplatin/chemokine modulatory combination regimen OCALA, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AMERICAN ) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today anno...

Benzinga | January 24, 2022

AIM ImmunoTech reports positive data from phase1/2 trial in ovarian cancer

AIM ImmunoTech <> announced positive data from a phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.The phase 1/2 study, which is

Seeking Alpha | January 24, 2022

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ETOCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present

Yahoo | January 19, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.

Yahoo | January 12, 2022

Critical Review: PharmaCyte Biotech (OTCMKTS:PMCBD) & AIM ImmunoTech (NYSE:AIM)

PharmaCyte Biotech (OTCMKTS:PMCBD) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Earnings and Valuation This table compares PharmaCyte Biotech and AIM ImmunoTechs gross revenue, earnings per [] The post Critical Review: PharmaCyte Biotech (OTCMKTS:PMCBD) & AIM ImmunoTech (NYSE:AIM) appeared first on ETF Daily News .

ETF Daily News | December 19, 2021

21,597 Shares in AIM ImmunoTech Inc. (NYSE:AIM) Acquired by Arkadios Wealth Advisors

Arkadios Wealth Advisors purchased a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,597 shares of the companys stock, valued at approximately $43,000. Other hedge funds have also recently added []

Transcript Daily | December 10, 2021

AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza

OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. The conference also included research on COVID-19 and respiratory syncytial virus. The Centre for Human Drug Research (CHDR) presented previously announced data from a Phase 1 clinical study to assess th

Yahoo | December 9, 2021

Critical Contrast: AIM ImmunoTech (AIM) & Its Competitors

AIM ImmunoTech (NYSE: AIM) is one of 237 public companies in the Biological products, except diagnostic industry, but how does it contrast to its peers? We will compare AIM ImmunoTech to related companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, earnings and institutional ownership. Profitability This table compares AIM ImmunoTech [] The post Critical Contrast: AIM ImmunoTech (AIM) & Its Competitors appeared first on ETF Daily News .

ETF Daily News | December 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4126 seconds.